An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety,
tolerability, and maximum tolerated dose of tivozanib (AV-951) with this dosing schedule, as
well as overall response rate of tivozanib (AV-951) administration in NSCLC.